The present invention relates to certain 4-substituted 1H-pyrrolo[2,3-b]pyridine compounds of the formula (I) and pharmaceutically acceptable salts thereof. These compounds is useful in the treatment or prevention of a disease or medical condition mediated through certain mutated forms of ErbB receptor, especially of Exon20 Her2 and EGFR mutations.

##STR00001##

Various aspects of this disclosure relate to a composition, comprising a liquid phase that consists of chemical species that comprise a solvent and solutes, wherein: each solute of the solutes is dissolved in the solvent of the liquid phase; each chemical species of the liquid phase has a concentration by mass in the liquid phase; the concentration by mass of the solvent in the liquid phase is greater than the concentration by mass of each solute of the liquid phase; the solvent is glycerol; the solutes comprise a cannabinoid; the liquid phase has a pressure and temperature; the cannabinoid has a solubility in glycerol at the pressure and temperature; the concentration by mass of the cannabinoid in the liquid phase is greater than the solubility of the cannabinoid in glycerol at the pressure and temperature; the composition is formulated for oral consumption; and the composition comprises at least 0.1 and no greater than 6 food calories per gram of the composition.

Various aspects of this disclosure relate to a composition, comprising a liquid phase that consists of chemical species that comprise a solvent and solutes, wherein: each solute of the solutes is dissolved in the solvent of the liquid phase; each chemical species of the liquid phase has a concentration by mass in the liquid phase; the concentration by mass of the solvent in the liquid phase is greater than the concentration by mass of each solute of the liquid phase; the solvent is glycerol; the solutes comprise a cannabinoid; the liquid phase has a pressure and temperature; the cannabinoid has a solubility in glycerol at the pressure and temperature; the concentration by mass of the cannabinoid in the liquid phase is greater than the solubility of the cannabinoid in glycerol at the pressure and temperature; the composition is formulated for oral consumption; and the composition comprises at least 0.1 and no greater than 6 food calories per gram of the composition.

The purpose of the invention is to develop, as drug-candidate compounds, a group of novel compounds having the activity of inhibiting functions of Pin1. The invention provides: a compound represented by formula (I) or a salt thereof; and a Pin1 inhibitor, a pharmaceutical composition, a therapeutic or prophylactic agent for inflammatory diseases, a therapeutic or prophylactic agent for cancer, and a therapeutic or prophylactic agent for adiposity that use said compound/salt. ##STR00001##

The purpose of the invention is to develop, as drug-candidate compounds, a group of novel compounds having the activity of inhibiting functions of Pin1. The invention provides: a compound represented by formula (I) or a salt thereof; and a Pin1 inhibitor, a pharmaceutical composition, a therapeutic or prophylactic agent for inflammatory diseases, a therapeutic or prophylactic agent for cancer, and a therapeutic or prophylactic agent for adiposity that use said compound/salt. ##STR00001##

This invention disclosed new use of R-terbutaline and other R-enantiomer β2-agonists as immune-modulators for treatment of bronchia-lung inflammatory symptoms or inflammatory fibrosis remolding. This invention also disclosed new use of R-terbutaline and R-β2-agonists for reduced adverse effects related to racemic or S-enantiomer β2-agonists including airway hyper responsiveness and airway fibrosis.

This invention disclosed new use of R-terbutaline and other R-enantiomer β2-agonists as immune-modulators for treatment of bronchia-lung inflammatory symptoms or inflammatory fibrosis remolding. This invention also disclosed new use of R-terbutaline and R-β2-agonists for reduced adverse effects related to racemic or S-enantiomer β2-agonists including airway hyper responsiveness and airway fibrosis.

This invention relates to novel compounds and pharmaceutical compositions comprising the same. Compounds of the invention useful as modulators of Rho-associated protein kinase (ROCK), for example ROCK1 and/or ROCK2 inhibitors. Methods of treatment employing the compounds are also contemplated by the present invention. The compounds of the invention are useful in treating ROCK mediated diseases.

This invention relates to novel compounds and pharmaceutical compositions comprising the same. Compounds of the invention useful as modulators of Rho-associated protein kinase (ROCK), for example ROCK1 and/or ROCK2 inhibitors. Methods of treatment employing the compounds are also contemplated by the present invention. The compounds of the invention are useful in treating ROCK mediated diseases.

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:

##STR00001##

which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.